Lung Cancer News

Squamous Cell Lung Cancer Cells Are Sugar-dependent

Squamous Cell Lung Cancer Cells Are Sugar-dependent

Squamous cell lung cancers, a form of NSCLC, are glucose-dependent, while adenocarcinoma NSCLC tumors are largely glucose-independent.

Lung Cancer Radiotherapy Might Improve Immune Checkpoint Blockade-associated Survival

Lung Cancer Radiotherapy Might Improve Immune Checkpoint Blockade-associated Survival

Researchers call for additional clinical trials investigating radiotherapy followed by immune checkpoint blockade for patients with NSCLC.

Neoadjuvant Nivolumab Shows Efficacy in Non-small Cell Lung Cancer

Neoadjuvant Nivolumab Shows Efficacy in Non-small Cell Lung Cancer

Neoadjuvant nivolumab is safe and provides a comparable pathologic response to that with cisplatin-based neoadjuvant chemotherapy in resectable non-small cell lung cancer.

Non-small Cell Lung Cancer: Neutrophil-lymphocyte Ratio Predicts Overall Survival

Non-small Cell Lung Cancer: Neutrophil-lymphocyte Ratio Predicts Overall Survival

The prognostic marker, which was evaluated among patients with stage III NSCLC, held after adjusting for variables including chemoradiation approach and performance status.

Liquid Biopsy Identifies EGFR-TKI Resistance Heterogeneity in Lung Cancer

Liquid Biopsy Identifies EGFR-TKI Resistance Heterogeneity in Lung Cancer

A liquid biopsy analysis shows inter- and intra-patient heterogeneity of EGFR resistance mutations among patients with lung adenocarcinoma who received EGFR-directed TKI therapy.

Affordable Care Act Increased Rate of Early Cancer Diagnoses

Affordable Care Act Increased Rate of Early Cancer Diagnoses

The US Affordable Care Act may have increased the proportion of patients with cancer diagnosed at stage I, according to a study.

Adjuvant Gefitinib Prolongs Disease-free Survival in Non-small Cell Lung Cancer

Adjuvant Gefitinib Prolongs Disease-free Survival in Non-small Cell Lung Cancer

Adjuvant gefitinib significantly prolongs disease-free survival compared with vinorelbine plus cisplatin among patients with stage II to III non-small cell lung cancer.

Sequential Durvalumab Prolongs Progression-free Survival in Stage III NSCLC

Sequential Durvalumab Prolongs Progression-free Survival in Stage III NSCLC

An interim analysis of the PACIFIC trial found that PFS was significantly prolonged compared with placebo.

Alectinib Beats Crizotinib in ALK-positive Non-small Cell Lung Cancer

Alectinib Beats Crizotinib in ALK-positive Non-small Cell Lung Cancer

Alectinib prolongs progression-free survival with less toxicity compared with crizotinib among Japanese patients with ALK-positive non-small cell lung cancer.

Pembrolizumab Approved for Previously Untreated Non-small Cell Lung Cancer

Pembrolizumab Approved for Previously Untreated Non-small Cell Lung Cancer

The FDA approved pembrolizumab in combination with pemetrexed and carboplatin as a first-line treatment for metastatic lung cancer.

Biomarker-driven Celecoxib Treatment Does Not Improve Survival Outcomes in NSCLC

Biomarker-driven Celecoxib Treatment Does Not Improve Survival Outcomes in NSCLC

Biomarker-driven treatment of non-small cell lung cancer with celecoxib failed to improve outcomes.

Varlilumab Active and Well-tolerated in Solid Tumors

Varlilumab Active and Well-tolerated in Solid Tumors

This anti-CD27 antibody demonstrated clinical activity among and was well-tolerated by patients with solid tumors including melanoma, prostate cancer, and renal cell carcinoma.

Phase 1 Trial of Palbociclib With Chemotherapy for Solid Tumors

Phase 1 Trial of Palbociclib With Chemotherapy for Solid Tumors

Safety, tolerability, and efficacy of palbociclib in combination with cisplatin or carboplatin among patients with advanced/metastatic solid tumors.

FDA Approves Brigatinib for ALK+ NSCLC After Crizotinib

FDA Approves Brigatinib for ALK+ NSCLC After Crizotinib

The FDA has approved brigatinib, a dual ALK and EGFR inhibitor, for the treatment of patients with ALK-positive NSCLC who progressed while receiving or are intolerant to crizotinib.

Chromosome Instability Associated With Death in NSCLC

Chromosome Instability Associated With Death in NSCLC

Chromosome instability was associated with an increased risk of recurrence and mortality among patients with early-stage NSCLC.

Lung Cancer: Timing May Affect EGFR mutation-related ctDNA Test Results

Lung Cancer: Timing May Affect EGFR mutation-related ctDNA Test Results

Timing might affect the results of an EGFR mutation-frequency circulating tumor DNA (ctDNA) test among patients with advanced NSCLC.

Proton Therapy Trial Among Patients With Stage I NSCLC

Proton Therapy Trial Among Patients With Stage I NSCLC

Researchers are evaluating whether hypoIGRT is an effective treatment strategy for patients with stage I NSCLC who are not candidates for surgery.

Phase 3 Trial of SPECT/CT Imaging for Lung Cancer

Phase 3 Trial of SPECT/CT Imaging for Lung Cancer

Researchers are attempting to determine whether SPECT/CT imaging is non-inferior to PET/CT imaging for lung cancer.

Clinician Communication, Perceived Burden Critical for Adherence to Oral Chemotherapy

Clinician Communication, Perceived Burden Critical for Adherence to Oral Chemotherapy

Patients who reported better clinician communication or an improved satisfaction with their treatment were more likely to be adherent.

Nivolumab Associated With Durable Long-term Responses in Lung Cancer

Nivolumab Associated With Durable Long-term Responses in Lung Cancer

Immune checkpoint inhibition with nivolumab is associated with durable clinical responses and a 16% 5-year survival rate among heavily pretreated patients with advanced NSCLC.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters